Open data
|
Deployed on AWS
The Cancer Genome Characterization Initiatives (CGCI) program supports cutting-edge genomics research of adult and pediatric cancers. CGCI investigators develop and apply advanced sequencing methods that examine genomes, exomes, and transcriptomes within various types of tumors. The program includes Burkitt Lymphoma Genome Sequencing Project (BLGSP) project and HIV+ Tumor Molecular Characterization Project - Cervical Cancer (HTMCP-CC) project.
The dataset contains open Clinical Supplement, Biospecimen Supplement, RNA-Seq Gene Expression Quantification, miRNA-Seq Isoform Expression Quantification, and miRNA Expression Quantification data.
This dataset also contains controlled WGS/Targeted Sequencing/RNA-Seq/miRNA-Seq Aligned Reads, and RNA-Seq Splice Junction Quantification
Overview
The Cancer Genome Characterization Initiatives (CGCI) program supports cutting-edge genomics research of adult and pediatric cancers. CGCI investigators develop and apply advanced sequencing methods that examine genomes, exomes, and transcriptomes within various types of tumors. The program includes Burkitt Lymphoma Genome Sequencing Project (BLGSP) project and HIV+ Tumor Molecular Characterization Project - Cervical Cancer (HTMCP-CC) project. The dataset contains open Clinical Supplement, Biospecimen Supplement, RNA-Seq Gene Expression Quantification, miRNA-Seq Isoform Expression Quantification, and miRNA Expression Quantification data. This dataset also contains controlled WGS/Targeted Sequencing/RNA-Seq/miRNA-Seq Aligned Reads, and RNA-Seq Splice Junction Quantification
Features and programs
Open Data Sponsorship Program
This dataset is part of the Open Data Sponsorship Program, an AWS program that covers the cost of storage for publicly available high-value cloud-optimized datasets.
Pricing
This is a publicly available data set. No subscription is required.
Legal
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
Delivery details
AWS Data Exchange (ADX)
AWS Data Exchange is a service that helps AWS easily share and manage data entitlements from other organizations at scale.
Open data resources
Available with or without an AWS account.
- How to use
- To access these resources, reference the Amazon Resource Name (ARN) using the AWS Command Line Interface (CLI). Learn more
- Description
- Clinical Supplement, Biospecimen Supplement, RNA-Seq Gene Expression Quantification, miRNA-Seq Isoform Expression Quantification, miRNA-Seq miRNA Expression Quantification
- Resource type
- S3 bucket
- Amazon Resource Name (ARN)
- arn:aws:s3:::gdc-cgci-blgsp-phs000235-2-open
- AWS region
- us-east-1
- AWS CLI access (No AWS account required)
- aws s3 ls --no-sign-request s3://gdc-cgci-blgsp-phs000235-2-open/
- Description
- Clinical Supplement, Biospecimen Supplement, RNA-Seq Gene Expression Quantification, miRNA-Seq Isoform Expression Quantification, miRNA-Seq miRNA Expression Quantification
- Resource type
- S3 bucket
- Amazon Resource Name (ARN)
- arn:aws:s3:::gdc-cgci-phs000235-2-open
- AWS region
- us-east-1
- AWS CLI access (No AWS account required)
- aws s3 ls --no-sign-request s3://gdc-cgci-phs000235-2-open/
- Description
- WGS/Targeted Sequencing/RNA-Seq/miRNA-Seq Aligned Reads, RNA-Seq Splice Junction Quantification
- Resource type
- S3 bucket
- Amazon Resource Name (ARN)
- arn:aws:s3:::gdc-cgci-phs000235-2-controlled
- AWS region
- us-east-1
- AWS CLI access (No AWS account required)
- aws s3 ls --no-sign-request s3://gdc-cgci-phs000235-2-controlled/
Resources
Vendor resources
Support
Contact
How to cite
Cancer Genome Characterization Initiatives - Burkitt Lymphoma, HIV+ Cervical Cancer was accessed on DATE from https://registry.opendata.aws/cgci .
License
NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies
Similar products
Machine Learning model to classify subjects’ susceptibility to lung cancer based on demographics, clinical measures and behavioral features.
Deep Learning model to predict the eligibility of a patient for a cancer clinical trial after going through patient's diagnosis notes.
Classifies fine-needle aspirates (FNA) of breast mass as benign or malignant
Identify risk of being diagnosed with Breast Cancer
Machine Learning model to predict the feasibility of a Clinical Trial